R&D/Clinical Trials

>

Latest News

Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus

May 21st 2025

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

May 15th 2025

Shaikh Vyvoda Mehta
Agile, Microlearning and Engaging Training for Clinical Trial Sites: A Strategic Approach to knowledge and learning management for Biotech Sponsors

May 14th 2025

Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders

May 14th 2025

Sujay Jadhav
How External Control Arms are Improving Clinical Trials: Q&A with Sujay Jadhav

May 9th 2025

More News